루핑일 백신 시장 규모, 점유율, 성장 분석 : 백신 유형별, 최종사용자별, 유통 경로별, 제제별, 지역별 - 업계 예측(2026-2033년)

Global Louping Ill Vaccines Market size was valued at USD 4.7 Billion in 2024 and is poised to grow from USD 5.06 Billion in 2025 to USD 9.16 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global louping ill vaccines market is primarily driven by the ongoing risk of tick-borne viral encephalitis affecting sheep and goats, prompting a focus on vaccination efforts by farmers and public health entities. This market encompasses veterinary biologics aimed at preventing neurological diseases that can lower flock productivity and jeopardize rural economies. Historical advancements have witnessed the evolution of inactivated vaccines and enhanced distribution strategies in high-risk regions, achieving greater awareness and surveillance. Regulatory harmonization and investments in veterinary infrastructure further lower adoption barriers, facilitating widespread immunization efforts. Additionally, cutting-edge developments in AI promote efficiency in vaccine development by streamlining candidate discovery, trial logistics, and predictive analytics, fostering interest from the private sector and enhancing market sustainability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Louping Ill Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Louping Ill Vaccines Market Segments Analysis

Global louping ill vaccines market is segmented by vaccine type, end user, distribution channel, formulation and region. Based on vaccine type, the market is segmented into Inactivated Vaccines and Live Attenuated Vaccines. Based on end user, the market is segmented into Veterinary Clinics and Research Institutions. Based on distribution channel, the market is segmented into Direct Sales, Online Retail and Distributors. Based on formulation, the market is segmented into Injectable Formulations and Oral Vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Louping Ill Vaccines Market

A key market driver for the Global Louping Ill Vaccines Market is the increasing incidence of louping ill disease in livestock, particularly sheep, which has raised awareness among farmers and veterinary professionals. The growing understanding of the disease's economic impact on livestock productivity and health is driving the demand for effective vaccination solutions. Additionally, advancements in vaccine technology and formulation are enhancing the efficacy and safety profiles of louping ill vaccines, further boosting their adoption. Furthermore, supportive government initiatives and funding aimed at disease prevention in agriculture are contributing significantly to the growth of this market, ensuring a proactive approach to livestock health management.

Restraints in the Global Louping Ill Vaccines Market

A significant restraint in the global louping ill vaccines market is the limited awareness and understanding of louping ill disease among livestock producers and veterinarians. This lack of knowledge can lead to lower vaccination rates, as many stakeholders may underestimate the disease's impact or fail to recognize the benefits of vaccination. Furthermore, budget constraints and competing health priorities may deter livestock owners from investing in vaccines, especially in regions where the disease is perceived as less prevalent. Consequently, this situation hinders market growth and affects the overall efficacy of disease management strategies in animal health.

Market Trends of the Global Louping Ill Vaccines Market

The Global Louping Ill Vaccines market is witnessing a significant trend towards integrated One Health initiatives that emphasize cross-sector collaboration among veterinary services, public health authorities, wildlife managers, and farming communities. This collaborative approach is redefining vaccination strategies, as coordinated surveillance and shared risk assessments facilitate targeted immunization campaigns in high-risk areas. By fostering trust and resource-sharing, these initiatives align veterinary practices with zoonotic disease management and public health priorities. The integration of animal health with human health and ecological factors is enhancing the adoption of vaccine programs, driving sustainable control efforts, and increasing stakeholder engagement in managing louping ill.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Louping Ill Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Inactivated Vaccines
  • Whole Virus Vaccines
  • Subunit Vaccines
• Live Attenuated Vaccines

Global Louping Ill Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Veterinary Clinics
• Research Institutions

Global Louping Ill Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Online Retail
• Distributors

Global Louping Ill Vaccines Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Injectable Formulations
• Oral Vaccines

Global Louping Ill Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, End User, Distribution Channel, Formulation)
  • US
  • Canada
• Europe (Vaccine Type, End User, Distribution Channel, Formulation)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, End User, Distribution Channel, Formulation)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, End User, Distribution Channel, Formulation)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, End User, Distribution Channel, Formulation)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hipra
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlogic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aggressopet
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmgate
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AgriLabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Animal Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations